Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON

Fig. 1

Percentage change from baseline in ApoB and ApoB-lipoprotein cholesterol with evolocumab vs placebo on background statin therapy. Values shown are means of weeks 10 and 12 except for ApoB, which was measured at week 12. All treatment differences between evolocumab and placebo are statistically significant at P < 0.0001. When the calculated LDL-C was < 1.0 mmol/L or TGs were > 4.5 mmol/L, calculated LDL-C was replaced with ultracentrifugation to inform LDL-C and VLDL-C from the same blood sample, if available. ApoB apolipoprotein B, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Lp(a) lipoprotein(a), non-HDL-C non-high-density lipoprotein cholesterol, Q2W every 2 weeks, QM monthly, TG triglycerides, VLDL-C very low-density lipoprotein cholesterol

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840